{"id":43159,"date":"2025-10-13T16:52:24","date_gmt":"2025-10-13T08:52:24","guid":{"rendered":"https:\/\/flcube.com\/?p=43159"},"modified":"2025-10-13T16:52:25","modified_gmt":"2025-10-13T08:52:25","slug":"boehringer-ingelheim-secures-fda-approval-for-nerandomilast-jascayd-in-idiopathic-pulmonary-fibrosis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=43159","title":{"rendered":"Boehringer Ingelheim Secures FDA Approval for Nerandomilast (JASCAYD) in Idiopathic Pulmonary Fibrosis"},"content":{"rendered":"\n<p>Boehringer Ingelheim (BI) announced today that the U.S. Food and Drug Administration (FDA) has approved its oral PDE4B\u2011selective inhibitor, <strong>nerandomilast<\/strong>, under the brand name <strong>JASCAYD<\/strong> for the treatment of adult patients with idiopathic pulmonary fibrosis (IPF).<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-fda-approval-highlights\">FDA Approval Highlights<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Indication<\/strong> \u2013 Adult IPF patients who are candidates for disease\u2011modifying therapy.<\/li>\n\n\n\n<li><strong>Brand<\/strong> \u2013 JASCAYD, 18\u202fmg or 9\u202fmg oral tablets.<\/li>\n\n\n\n<li><strong>Regulatory Milestone<\/strong> \u2013 First FDA approval for an oral PDE4B inhibitor in IPF, expanding the therapeutic options for this progressive lung disease.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-clinical-evidence\">Clinical Evidence<\/h3>\n\n\n\n<p>The approval was based on two pivotal Phase\u202fIII studies:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Trial<\/th><th>NCT ID<\/th><th>Primary Endpoint<\/th><th>Key Results<\/th><\/tr><\/thead><tbody><tr><td>FIBRONEER\u2011IPF<\/td><td>NCT05321069<\/td><td>Absolute change in Forced Vital Capacity (FVC) at week\u202f52<\/td><td>Nerandomilast 18\u202fmg: \u2212106\u202fmL; 9\u202fmg: \u2212122\u202fmL; Placebo: \u2212170\u202fmL<\/td><\/tr><tr><td>Trial\u202f2<\/td><td>NCT04419506<\/td><td>Same endpoint<\/td><td>Similar benefit profile, reinforcing consistency across cohorts<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Early Efficacy<\/strong> \u2013 A clinically meaningful decline in FVC was observed as early as week\u202f2 in the 18\u202fmg cohort, with the treatment effect widening through week\u202f52.<\/li>\n\n\n\n<li><strong>Safety Profile<\/strong> \u2013 Adverse events were manageable and comparable to placebo, reinforcing the drug\u2019s tolerability in a chronic\u2011disease setting.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-market-implications\">Market Implications<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First\u2011Mover Advantage<\/strong> \u2013 JASCAYD represents the first oral PDE4B\u2011selective agent in the IPF market, a niche with limited pharmacologic options beyond antifibrotic agents.<\/li>\n\n\n\n<li><strong>Pricing &amp; Reimbursement<\/strong> \u2013 Boehringer Ingelheim plans a value\u2011based pricing strategy aligned with the drug\u2019s ability to slow lung function decline, potentially positioning JASCAYD favorably in payer negotiations.<\/li>\n\n\n\n<li><strong>Pipeline Synergy<\/strong> \u2013 The approval strengthens Boehringer\u2019s respiratory portfolio, complementing its existing antifibrotic and anti\u2011inflammatory products.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-company-perspective\">Company Perspective<\/h3>\n\n\n\n<p>\u201c<strong>We are proud to deliver a new, evidence\u2011based therapy for patients suffering from idiopathic pulmonary fibrosis.<\/strong>\u201d said Dr.\u202fSarah\u202fM.\u202fKirk, President of Boehringer Ingelheim Respiratory. \u201cThe robust clinical data from FIBRONEER\u2011IPF and our Phase\u202fIII program demonstrate that nerandomilast can meaningfully slow disease progression, offering hope to a patient population with limited options.\u201d<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-outlook\">Outlook<\/h3>\n\n\n\n<p>Boehringer Ingelheim will begin commercial distribution of JASCAYD in the U.S. in the first half of 2026, with global launch planned in the second half of 2026 following regulatory approvals in other markets. The company will continue to expand the indication portfolio for nerandomilast, leveraging its favorable safety profile and mechanistic rationale in other fibrotic and inflammatory diseases.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boehringer Ingelheim (BI) announced today that the U.S. Food and Drug Administration (FDA) has approved&#8230;<\/p>\n","protected":false},"author":1,"featured_media":43160,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[11],"tags":[390,15,24],"class_list":["post-43159","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-drug","tag-boehringer-ingelheim","tag-product-approvals","tag-rare-orphan-disease-drugs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Boehringer Ingelheim Secures FDA Approval for Nerandomilast (JASCAYD) in Idiopathic Pulmonary Fibrosis - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Boehringer Ingelheim (BI) announced today that the U.S. Food and Drug Administration (FDA) has approved its oral PDE4B\u2011selective inhibitor, nerandomilast, under the brand name JASCAYD for the treatment of adult patients with idiopathic pulmonary fibrosis (IPF).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=43159\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Boehringer Ingelheim Secures FDA Approval for Nerandomilast (JASCAYD) in Idiopathic Pulmonary Fibrosis\" \/>\n<meta property=\"og:description\" content=\"Boehringer Ingelheim (BI) announced today that the U.S. Food and Drug Administration (FDA) has approved its oral PDE4B\u2011selective inhibitor, nerandomilast, under the brand name JASCAYD for the treatment of adult patients with idiopathic pulmonary fibrosis (IPF).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=43159\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-13T08:52:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-13T08:52:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1303.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43159#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43159\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Boehringer Ingelheim Secures FDA Approval for Nerandomilast (JASCAYD) in Idiopathic Pulmonary Fibrosis\",\"datePublished\":\"2025-10-13T08:52:24+00:00\",\"dateModified\":\"2025-10-13T08:52:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43159\"},\"wordCount\":381,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43159#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1303.webp\",\"keywords\":[\"Boehringer Ingelheim\",\"Product approvals\",\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43159#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43159\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=43159\",\"name\":\"Boehringer Ingelheim Secures FDA Approval for Nerandomilast (JASCAYD) in Idiopathic Pulmonary Fibrosis - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43159#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43159#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1303.webp\",\"datePublished\":\"2025-10-13T08:52:24+00:00\",\"dateModified\":\"2025-10-13T08:52:25+00:00\",\"description\":\"Boehringer Ingelheim (BI) announced today that the U.S. Food and Drug Administration (FDA) has approved its oral PDE4B\u2011selective inhibitor, nerandomilast, under the brand name JASCAYD for the treatment of adult patients with idiopathic pulmonary fibrosis (IPF).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43159#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43159\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43159#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1303.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1303.webp\",\"width\":1080,\"height\":608,\"caption\":\"Boehringer Ingelheim Secures FDA Approval for Nerandomilast (JASCAYD) in Idiopathic Pulmonary Fibrosis\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43159#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Boehringer Ingelheim Secures FDA Approval for Nerandomilast (JASCAYD) in Idiopathic Pulmonary Fibrosis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Boehringer Ingelheim Secures FDA Approval for Nerandomilast (JASCAYD) in Idiopathic Pulmonary Fibrosis - Insight, China&#039;s Pharmaceutical Industry","description":"Boehringer Ingelheim (BI) announced today that the U.S. Food and Drug Administration (FDA) has approved its oral PDE4B\u2011selective inhibitor, nerandomilast, under the brand name JASCAYD for the treatment of adult patients with idiopathic pulmonary fibrosis (IPF).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=43159","og_locale":"en_US","og_type":"article","og_title":"Boehringer Ingelheim Secures FDA Approval for Nerandomilast (JASCAYD) in Idiopathic Pulmonary Fibrosis","og_description":"Boehringer Ingelheim (BI) announced today that the U.S. Food and Drug Administration (FDA) has approved its oral PDE4B\u2011selective inhibitor, nerandomilast, under the brand name JASCAYD for the treatment of adult patients with idiopathic pulmonary fibrosis (IPF).","og_url":"https:\/\/flcube.com\/?p=43159","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-13T08:52:24+00:00","article_modified_time":"2025-10-13T08:52:25+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1303.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=43159#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=43159"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Boehringer Ingelheim Secures FDA Approval for Nerandomilast (JASCAYD) in Idiopathic Pulmonary Fibrosis","datePublished":"2025-10-13T08:52:24+00:00","dateModified":"2025-10-13T08:52:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=43159"},"wordCount":381,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=43159#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1303.webp","keywords":["Boehringer Ingelheim","Product approvals","Rare \/ orphan disease drugs"],"articleSection":["Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=43159#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=43159","url":"https:\/\/flcube.com\/?p=43159","name":"Boehringer Ingelheim Secures FDA Approval for Nerandomilast (JASCAYD) in Idiopathic Pulmonary Fibrosis - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=43159#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=43159#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1303.webp","datePublished":"2025-10-13T08:52:24+00:00","dateModified":"2025-10-13T08:52:25+00:00","description":"Boehringer Ingelheim (BI) announced today that the U.S. Food and Drug Administration (FDA) has approved its oral PDE4B\u2011selective inhibitor, nerandomilast, under the brand name JASCAYD for the treatment of adult patients with idiopathic pulmonary fibrosis (IPF).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=43159#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=43159"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=43159#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1303.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1303.webp","width":1080,"height":608,"caption":"Boehringer Ingelheim Secures FDA Approval for Nerandomilast (JASCAYD) in Idiopathic Pulmonary Fibrosis"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=43159#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Boehringer Ingelheim Secures FDA Approval for Nerandomilast (JASCAYD) in Idiopathic Pulmonary Fibrosis"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1303.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43159","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=43159"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43159\/revisions"}],"predecessor-version":[{"id":43161,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43159\/revisions\/43161"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/43160"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=43159"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=43159"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=43159"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}